D. E. Shaw & Co., Inc. Dr Reddys Laboratories LTD Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$64.27 - $69.9 $652,854 - $710,044	10,158 New	10,158 $706,000
Q2 2023 Aug 14, 2023	SELL	$53.34 - $63.11 $5.89 Million - $6.97 Million	-110,385 Reduced 79.87%	27,817 $1.76 Million
Q1 2023 May 15, 2023	BUY	$51.63 - $56.93 $3.38 Million - $3.73 Million	65,444 Added 89.95%	138,202 $7.87 Million
Q4 2022 Feb 14, 2023	SELL	$51.15 - $57.45 $839,320 - $942,697	-16,409 Reduced 18.4%	72,758 $3.77 Million
Q3 2022 Nov 14, 2022	SELL	$49.9 - $57.32 $7.78 Million - $8.93 Million	-155,856 Reduced 63.61%	89,167 $4.67 Million

Q2 2022 Aug 15, 2022	SELL	$49.62 - $58.13 $2.87 Million - $3.36 Million	-57,746 Reduced 19.07%	245,023 $13.6 Million
Q1 2022 May 16, 2022	BUY	$48.27 - $65.25 $7.46 Million - $10.1 Million	154,502 Added 104.21%	302,769 $16.9 Million
Q4 2021 Feb 14, 2022	BUY	$59.5 - $67.25 $3.55 Million - $4.02 Million	59,722 Added 67.45%	148,267 $9.7 Million
Q3 2021 Nov 15, 2021	SELL	$60.19 - $75.29 $4.01 Million - $5.02 Million	-66,631 Reduced 42.94%	88,545 $5.77 Million
Q2 2021 Aug 16, 2021	BUY	$62.12 - $74.2 $1.69 Million - $2.02 Million	27,227 Added 21.28%	155,176 $11.4 Million
Q1 2021 May 17, 2021	SELL	$57.98 - $73.08 $1.02 Million - $1.29 Million	-17,634 Reduced 12.11%	127,949 $7.86 Million
Q4 2020 Feb 16, 2021	BUY	$62.61 - $71.29 $224,269 - $255,360	3,582 Added 2.52%	145,583 $10.4 Million
Q3 2020 Nov 16, 2020	SELL	$51.39 - $72.41 $756,255 - $1.07 Million	-14,716 Reduced 9.39%	142,001 $9.88 Million
Q2 2020 Aug 14, 2020	SELL	$39.55 - $54.65 $4.18 Million - $5.78 Million	-105,752 Reduced 40.29%	156,717 $8.31 Million
Q1 2020 May 15, 2020	SELL	$34.75 - $45.85 $744,414 - $982,198	-21,422 Reduced 7.55%	262,469 $10.6 Million
Q4 2019 Feb 14, 2020	BUY	$36.66 - $41.78 $2.06 Million - $2.35 Million	56,157 Added 24.66%	283,891 $11.5 Million
Q3 2019 Nov 14, 2019	BUY	$34.82 - $39.26 $1.33 Million - $1.5 Million	38,295 Added 20.21%	227,734 $8.63 Million
Q2 2019 Aug 14, 2019	SELL	$36.05 - $42.76 $3.91 Million - $4.64 Million	-108,419 Reduced 36.4%	189,439 $7.1 Million
Q1 2019 May 15, 2019	SELL	$35.77 - $40.57 $639,317 - $725,107	-17,873 Reduced 5.66%	297,858 $12.1 Million
Q4 2018 Feb 14, 2019	BUY	$31.89 - $38.44 $83,711 - $100,905	2,625 Added 0.84%	315,731 $11.9 Million
Q3 2018 Nov 14, 2018	SELL	$29.25 - $36.73 $6.21 Million - $7.79 Million	-212,217 Reduced 40.4%	313,106 $10.8 Million
Q2 2018 Aug 14, 2018	BUY	$28.49 - $35.06 $13.6 Million - $16.8 Million	477,848 Added 1006.53%	525,323 $16.9 Million
Q1 2018 May 15, 2018	BUY	$31.93 - $39.54 $1.52 Million - $1.88 Million	47,475 New	47,475 $1.55 Million
Q4 2017 Feb 14, 2018	SELL	$34.15 - $37.62 $927,172 - $1.02 Million	-27,150 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$30.11 - $37.72 $817,486 - $1.02 Million	27,150	27,150 $969,000

Others Institutions Holding RDY

# of Institutions

242

Shares Held

23.6M

Call Options Held

25.2K

Put Options Held

8.5K

Black Rock Inc. New York, NY

2.18M
Shares

$166 Million
0.0% of portfolio
Royal Bank Of Canada Toronto, A6

2.16M
Shares

$165 Million
0.04% of portfolio
Robeco Institutional Asset Management B.V.

1.97M
Shares

$150 Million
0.32% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.93M
Shares

$147 Million
0.22% of portfolio
Goldman Sachs Group Inc New York, NY

1.56M
Shares

$119 Million
0.02% of portfolio

View Full List

About DR REDDYS LABORATORIES LTD

Ticker RDY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 166,028,992
Market Cap $12.6B
Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-t...

More about RDY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account